New indication for Abraxane

24 Sep 2013 9:54 PM | Lori Aubrey (Administrator)

FDA approves Abraxane for late-stage pancreatic cancer.

On September 6, 2013, the U.S. Food and Drug Administration expanded the approved use of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer death in the United States. An estimated 45,220 patients will be diagnosed and 38,460 will die from the disease in 2013, according to the National Cancer Institute. Surgery is the only option to permanently remove or cure pancreatic cancer, but it usually is too late for surgery by the time the cancer is diagnosed.

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm367442.htm

FDA Approvals

Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software